Efficacy of Combination Therapy with Lenvatinib, Programmed Cell Death 1 Inhibitors and Transarterial Therapy: a Propensity Score-Matching Cohort Study

Mengran Lang,Leijuan Gan,Shaohua Ren,Xiaochen Ma,Guangtao Li,Huikai Li,Ti Zhang,Wanmin Qiang,Yunlong Cui,Wei Zhang,Feng Fang,Qiang Li,Wei Lü,Tianqiang Song

DOI: https://doi.org/10.21203/rs.3.rs-1698950/v1

2022-01-01

Abstract:Purpose Few studies have investigated the efficacy of triple combination therapy with lenvatinib, programmed cell death 1 (PD-1) inhibitors and transarterial therapy in patients with intermediate/advanced hepatocellular carcinoma (HCC). Patients and methods We retrospectively analyzed patients with intermediate/advanced HCC treated at Tianjin Cancer Hospital from December 2018 to October 2020 and compared outcomes of lenvatinib plus PD-1 inhibitors and transarterial therapy (LEN-PD1-TH) versus lenvatinib and PD-1 inhibitors (LENPD1). Propensity score-matching was used. The primary study endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS) and overall response rate (ORR) assessed using modified RECIST. The Cox proportional hazards model was used to identify factors that affected prognosis. Results In total, 152 patients were included. Propensity score matching led to 35 matched patients in each group. The median follow-up time was 14 months (95% CI, 10.1-17.9) as of May 2021. The LEN-PD1-TH group had a longer median PFS and OS versus the LEN-PD1 group (15 vs. 9 months; P=0.004 and 14 months vs. NA; P<0.001, respectively). The ORR was significantly higher in the LEN-PD1-TH group versus the LEN-PD1 group (42.9 vs. 20.1%; P=0.039). In multivariate analysis, all triple therapy regimens were associated with improved PFS (hazard ratio [HR]=0.362; 95% CI, 0.185-0.771; P=0.003) and OS (HR=0.143; 95% CI, 0.053-0.383; P<0.001). Child-Pugh class B and Barcelona clinic liver cancer stage (BCLC) C disease were identified as risk factors for PFS, and large tumor size was a risk factor for OS. Patients with extrahepatic metastases, no vascular invasion, tumor diameter <10 cm, tumor number >3, BCLC stage C, and alpha-fetoprotein ≤400 ng/ml showed a tendency to benefit from the triple therapy regimen. The addition of transarterial therapy to lenvatinib and PD-1 inhibitors did not significantly increase adverse reactions. Conclusions LEN-PD1-TH improved survival outcomes for patients with intermediate to advanced HCC compared to LEN-PD1.